Amgen’s stock slides after weight-loss drug data lags analyst expectations

Published on 26 Nov 2024 on Market Watch

Amgen’s MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up...

Read the rest of the article

Start tracking your investments with Statfolio

We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus ...

Insider Monkey · via Yahoo Finance 1 Dec 2024

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is...

Zacks · via Yahoo Finance 29 Nov 2024

The S&P 500 index rose 0.2%, while the Nasdaq Composite climbed more than 0.5%. The Dow Jones...

Invezz 26 Nov 2024

Amgen’s MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting u...

Market Watch 26 Nov 2024

Amgen Inc (NASDAQ: AMGN) says patients on its weight-loss injection in a mid-stage trial weighed ...

Invezz 26 Nov 2024

On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company...

Benzinga · via AOL 26 Nov 2024

Investors are anxious about the impact of the incoming administration of President-elect Donald T...

Los Angeles Business Journal 25 Nov 2024

Explore our interactive list of high quality stocks to get an idea of what else is out there you ...

Simply Wall St. · via Yahoo Finance 24 Nov 2024

United States shares mixed at close of trade; Dow Jones Industrial Average up 0.32%

Investing.com 20 Nov 2024

On Monday, Silence Therapeutics plc (NASDAQ:SLN) presented end-of-treatment data from its Phase 2...

Benzinga · via Yahoo Finance 19 Nov 2024